Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 12, 2014, Pages 2965-2970

  Gatalica, Zoran ^a   Snyder, Carrie ^b   Maney, Todd ^a   Ghazalpour, Anatole ^a   Holterman, Daniel A ^a   Xiao, Nianqing ^a   Overberg, Peggy ^a   Rose, Inga ^a   Basu, Gargi D ^a   Vranic, Semir ^c   Lynch, Henry T ^b   Von Hoff, Daniel D ^d   Hamid, Omid ^e  

^a CARIS LIFE SCIENCES   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^d Virginia G Piper Charitable Trust   (United States)

^e Angeles Clinic and Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN; PROTEIN ALK; PROTEIN P53; PROTEIN ROS1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER CELL; CARCINOMA; CHONDROSARCOMA; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; ENDOMETRIUM CANCER; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LIPOSARCOMA; MAJOR CLINICAL STUDY; MELANOMA; MERKEL CELL TUMOR; MICROSATELLITE MARKER; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; SARCOMA; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; ANTAGONISTS AND INHIBITORS; DISEASE COURSE; FEMALE; GENETICS; MALE; NEOPLASM; PROGNOSIS;

DISEASE PROGRESSION; FEMALE; HUMANS; MALE; NEOPLASMS; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84919385463     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0654     Document Type: Article

References (25)

1. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013; 19: 1021-34.
2. Hodi FS, O'Day SJ, McDermott DF, Weber R.W., Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
3. Hamid O, Robert C, Daud A., Hodi FS, Hwu WJ, Kefford J, et al Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-44.
4. Brahmer JR, Tykodi SS, Chow L.Q., Hwu WJ, Topalian SL, Hwu P, et al Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-65.
5. Topalian SL, Hodi FS, Brahmer J.R., Gettinger SN, Smith DC, McDermott DF, et al Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
6. Topalian SL, Sznol M, McDermott D.F., Kluger HM, Carvajal RD, Sharfman WH, et al Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32: 1020-30.
7. Velcheti V, Schalper KA, Carvajal D.E., Anagnostou VK, Syrigos KN, Sznol M, et al Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014; 94: 107-16.
8. Millis S, Bryant D, Basu G., Bender R, Vranic S, Gatalica Z., et al. Molecular profiling of infiltrating urothelial carcinomaof the bladder. Clin Genitourin Cancer 2014 Aug 1. [Epub ahead of print].
9. Ghebeh H, Mohammed S, Al-Omair A, Qattan A., Lehe C, Al-Quadihi G, et al. The B7-H1 (PDL1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006; 8: 190-8.
10. Muenst S, Soysal SD, Gao F, Obermann E.C., Oertli D., Gillanders WE. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2013; 139: 667-76.
11. Weidner N. Measuring intratumoral microvessel density. Methods Enzymol 2008; 444: 305-23.
12. Lipson EJ, Vicent JG, Loyo M, Kagohara L.T., Luber BS, Wang H, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 2013; 1: 54-63.
13. Taube JM, Klein AP, Brahmer J.R., Xu H., Pan X, Kim JH, et al Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014 Apr 8. [Epub ahead of print].
14. Langer CJ. Emerging immunotherapies in the treatment of Non-Small Cell Lung Cancer (NSCLC): the role of immune checkpoint inhibitors. Am J Clin Oncol 2014 Mar 28. [Epub ahead of print].
15. Jilaveanu LB, Shuch B, Zito C.R., Parisi F., Barr M, Kluger Y, et al PD-L1 expression in clear cell renal cell carcinoma: an analysis of nephrec-tomy and sites of metastases. J Cancer 2014; 5: 166-72.
16. Vanderstraeten A, Luyten C, Verbist G., Tuyaerts S, Amant F. Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunol Immunother 2014; 63: 545-57.
17. Kim JR, Moon YJ, Kwon K.S., Bae JS, Wagle S, Kim KM, et al Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS ONE 2013; 8: e82870.
18. Muenst S, Schaerli AR, Gao F, Däster S, Trella E., Droeser RA, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2014; 146: 15-24.
19. Sun S, Fei X, Mao Y., Wang X, Garfield DH, Huang O, et al PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol Immunother 2014; 63: 395-406.
20. Schreiber RD, Old LJ, Smyth MJ Cancer immunoediting: integrating immunity's role in cancer suppression and promotion. Science 2011; 331: 1565-70.
21. Kmieciak M, Payne KK, Wang X-Y, Manjili MH. IFN-g Ra is a key determinant of CD8+ T cell-mediated tumor elimination of tumor escape and relapse in FVB mouse. PLoS ONE 2013; 8:e82544.
22. Hallermalm K, Seki K, De Geer A, Motyka B, Bleackley R.C., Jager MJ, et al. Modulation of the tumor cell phenotype by IFN-g results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes. J Immunol 2008; 180: 3766-74.
23. Droeser RA, Hirt C, Viehl C.T., Frey DM, Nebiker C, Huber X, et al Clinical impact of programmed cell death ligant 1 expression in colorectal cancer. Eur J Cancer 2013; 49: 2233-42.
24. Yang CY, Lin MW, Chang Y.L., Wu CT, Yang PC. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 2014; 50: 1361-9.
25. Akbay EA, Koyama S, Carretero J., Altabef A, Tchaicha JH, Christensen C.L., et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 3: 1355-63.